Literature DB >> 19154178

Total synthesis and evaluation of iso-duocarmycin SA and iso-yatakemycin.

Karen S MacMillan1, Trinh Nguyen, Trihn Nguyen, Inkyu Hwang, Dale L Boger.   

Abstract

The total synthesis and evaluation of iso-duocarmycin SA (5) and iso-yatakemycin (6), representing key analogues of the corresponding natural products incorporating an isomeric alkylation subunit, are detailed. This pyrrole isomer of the natural alkylation subunit displayed an enhanced reaction regioselectivity and a 2-fold diminished stability. Although still exceptionally potent, the iso-duocarmycin SA derivatives and natural product analogues exhibited a corresponding approximate 3-5-fold reduction in cytotoxic activity [L1210 IC(50) for (+)-iso-duocarmycin SA = 50 pM and for (+)-iso-yatakemycin = 15 pM] consistent with their placement on a parabolic relationship correlating activity with reactivity. The DNA alkylation selectivity of the resulting key natural product analogues was unaltered by the structure modification in spite of the minor-groove presentation of a potential H-bond donor. Additionally, a unique ortho-spirocyclization with such derivatives was explored via the preparation, characterization, and evaluation of 34 that is incapable of the more conventional para-spirocyclization. Although 34 proved sufficiently stable for isolation and characterization, it displayed little stability in protic solvents (t(1/2) = 0.19 h at pH 3, t(1/2) = 0.20 h at pH 7), a pH-independent (H(+) independent) solvolysis rate profile at pH 3/4-7, and a much reduced cytotoxic potency, but a DNA alkylation selectivity and efficiency comparable to those of duocarmycin SA and iso-duocarmycin SA. The implications of these observations on the source of the DNA alkylation selectivity and catalysis for this class of natural products are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19154178      PMCID: PMC2646182          DOI: 10.1021/ja808108q

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  28 in total

1.  CC-1065 and the Duocarmycins: Synthetic Studies.

Authors:  Dale L. Boger; Christopher W. Boyce; Robert M. Garbaccio; Joel A. Goldberg
Journal:  Chem Rev       Date:  1997-05-08       Impact factor: 60.622

Review 2.  Mechanisms of in situ activation for DNA-targeting antitumor agents.

Authors:  Scott E Wolkenberg; Dale L Boger
Journal:  Chem Rev       Date:  2002-07       Impact factor: 60.622

3.  Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp.

Authors:  M Ichimura; T Ogawa; K Takahashi; E Kobayashi; I Kawamoto; T Yasuzawa; I Takahashi; H Nakano
Journal:  J Antibiot (Tokyo)       Date:  1990-08       Impact factor: 2.649

4.  Systematic exploration of the structural features of yatakemycin impacting DNA alkylation and biological activity.

Authors:  Mark S Tichenor; Karen S MacMillan; John D Trzupek; Thomas J Rayl; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2007-08-11       Impact factor: 15.419

5.  The DNA phosphate backbone is not involved in catalysis of the duocarmycin and CC-1065 DNA alkylation reaction.

Authors:  Yves Ambroise; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2002-02-11       Impact factor: 2.823

6.  Molecular basis for sequence-specific DNA alkylation by CC-1065.

Authors:  L H Hurley; C S Lee; J P McGovren; M A Warpehoski; M A Mitchell; R C Kelly; P A Aristoff
Journal:  Biochemistry       Date:  1988-05-17       Impact factor: 3.162

7.  CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity.

Authors:  D G Martin; C Biles; S A Gerpheide; L J Hanka; W C Krueger; J P McGovren; S A Mizsak; G L Neil; J C Stewart; J Visser
Journal:  J Antibiot (Tokyo)       Date:  1981-09       Impact factor: 2.649

8.  A short total synthesis of aureothin and N-acetylaureothamine.

Authors:  Mikkel F Jacobsen; John E Moses; Robert M Adlington; Jack E Baldwin
Journal:  Org Lett       Date:  2005-02-17       Impact factor: 6.005

9.  Solution kinetics of CC-1065 A-ring opening: substituent effects and general acid/base catalysis.

Authors:  Daniel V LaBarbera; Edward B Skibo
Journal:  J Am Chem Soc       Date:  2006-03-22       Impact factor: 15.419

Review 10.  CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents.

Authors:  D L Boger; D S Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

View more
  16 in total

1.  Synthesis and evaluation of duocarmycin SA analogs incorporating the methyl 1,2,8,8a-tetrahydrocyclopropa[c]oxazolo[2,3-e]indol-4-one-6-carboxylate (COI) alkylation subunit.

Authors:  Kristopher E Boyle; Karen S MacMillan; David A Ellis; James P Lajiness; William M Robertson; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-02-02       Impact factor: 2.823

2.  Synthesis and antitumor molecular mechanism of agents based on amino 2-(3',4',5'-trimethoxybenzoyl)benzo[b]furan: inhibition of tubulin and induction of apoptosis.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Carlota Lopez-Cara; Olga Cruz-Lopez; Maria Dora Carrion; Maria Kimatrai Salvador; Jaime Bermejo; Sara Estévez; Francisco Estévez; Jan Balzarini; Andrea Brancale; Antonio Ricci; Longchuan Chen; Jae Gwan Kim; Ernest Hamel
Journal:  ChemMedChem       Date:  2011-08-01       Impact factor: 3.466

3.  A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.

Authors:  Mika Uematsu; Daniel M Brody; Dale L Boger
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

4.  Synthesis and evaluation of a series of C5'-substituted duocarmycin SA analogs.

Authors:  William M Robertson; David B Kastrinsky; Inkyu Hwang; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-03-25       Impact factor: 2.823

5.  Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Douglas Brown; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2013-05-10       Impact factor: 7.446

6.  A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Scott J Weir; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2012-06-12       Impact factor: 7.446

7.  Synthesis and evaluation of a thio analogue of duocarmycin SA.

Authors:  Karen S MacMillan; James P Lajiness; Carlota Lopez Cara; Romeo Romagnoli; William M Robertson; Inkyu Hwang; Pier Giovanni Baraldi; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2009-10-17       Impact factor: 2.823

Review 8.  Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065.

Authors:  Karen S MacMillan; Dale L Boger
Journal:  J Med Chem       Date:  2009-10-08       Impact factor: 7.446

9.  Synthesis and evaluation of duocarmycin SA analogs incorporating the methyl 1,2,8,8a-tetrahydrocyclopropa[c]imidazolo[4,5-e]indol-4-one-6-carboxylate (CImI) alkylation subunit.

Authors:  Prem B Chanda; Kristopher E Boyle; Daniel M Brody; Vyom Shukla; Dale L Boger
Journal:  Bioorg Med Chem       Date:  2016-04-26       Impact factor: 3.641

10.  A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.

Authors:  Amanda L Wolfe; Katharine K Duncan; James P Lajiness; Kaicheng Zhu; Adam S Duerfeldt; Dale L Boger
Journal:  J Med Chem       Date:  2013-08-29       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.